This policy brief explores the importance of accelerated approval for advancing gene therapies targeting rare diseases. It outlines how regulatory flexibility can help support innovation for small patient populations with urgent unmet needs.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
